Skip to main content

Spinal Cord Injury

Spinal cord injury (SCI) is the archetypal reconstructive neuro-urology population. Nearly 100% of patients with SCI above the conus develop NLUTD, and without structured urologic surveillance CKD / ESRD was historically the leading cause of mortality. The level of injury, completeness, and interval since injury all drive the NLUTD phenotype. Sean Elliott and others have emphasized that the urologist's role in SCI is longitudinal — from the acute spinal-shock catheter drainage through decades of risk-stratified surveillance and, when necessary, reconstructive surgery.[1][2][3]

This article focuses on SCI-specific points. For general NLUTD principles see Neurogenic Lower Urinary Tract Dysfunction; for a life-threatening SCI-specific emergency see Autonomic Dysreflexia. For the reconstructive procedures referenced throughout, see Intradetrusor OnabotulinumtoxinA, Bladder Augmentation, Catheterizable Channels, and the Ileal Conduit salvage pathway.

Epidemiology​

  • US prevalence ~250,000–300,000; incidence ~17,000/year.
  • Leading etiologies: motor-vehicle trauma, falls, violence, sports, non-traumatic (transverse myelitis, tumor, ischemia).
  • Average age at injury is rising (currently ~43 years) — aging of the SCI population brings coexisting BPH, prostate cancer, and obesity into reconstructive planning.
  • Life expectancy in SCI has approached general-population levels for C5 and below; upper-tract complications and pressure injury remain leading preventable causes of death.

Pathophysiology by Level​

Injury levelPhase after injuryDominant urodynamic phenotype
Any levelAcute / spinal-shock (days–~6 weeks, range up to months)Detrusor areflexia + intact distal sphincter tone; urinary retention
Above T6 (high cervical / upper thoracic)After spinal shockDetrusor overactivity + DSD + risk of autonomic dysreflexia
T6–T12 / suprasacralAfter spinal shockDO + DSD; lower AD risk
Conus (T12–L1 region)Stable from onsetVariable — can resemble suprasacral DSD or sacral areflexia
Cauda equina / sacral / infrasacralStable from onsetDetrusor areflexia + denervated EUS; retention, overflow, stress incontinence

Initial Evaluation and Surveillance Cadence​

Per AUA/SUFU 2021 risk-stratified framework.[1][2] SCI generally requires assessment as unknown-risk, followed by classification using renal function, imaging, and urodynamics. Reassess when neurological function stabilizes, with earlier investigation for concerning changes. See the NLUTD risk and surveillance framework.

Baseline workup (timed to clinical stability and risk):

  • History + exam (including AD triggers, skin, bowel program)
  • Urinalysis, serum Cr / eGFR
  • Renal ultrasound
  • Video-urodynamics — documents DO, DSD, DLPP, compliance, VUR
  • PVR + bladder diary

Longitudinal surveillance (high-risk):

  • Annual clinical review; obtain urine testing for symptoms rather than routine infection screening
  • Renal ultrasound annually for high-risk disease; the 1–2-year interval belongs to stable moderate-risk disease
  • eGFR annually
  • Urodynamics when clinical change (new symptoms, hydronephrosis, declining function, new AD pattern)
  • Cystoscopy for an indication such as hematuria, recurrent UTI, or suspected structural pathology; not annual screening solely because a catheter is present

Management​

Emptying strategies — order of preference[2][3][4]​

  1. Clean intermittent catheterization (CIC) — the gold standard. 4–6×/day; hydrophilic or closed-system kits reduce UTI and urethral trauma.
  2. Indwelling SPC — when dexterity / caregiver support / body habitus preclude CIC. Preferred over indwelling urethral catheter in men to protect the urethra.
  3. Indwelling urethral catheter — last-line; high urethral-erosion risk in men, bladder-neck and sphincter damage in women.
  4. Reflex voiding with external condom drainage (men) — historically common; requires confirmed safe pressures and no DSD. Reflex voiding women: not practical — no condom-drainage equivalent.
  5. Credé / Valsalva — avoid in suprasacral lesions (raises storage pressure); consider only if urodynamics establish safe pressures and effective emptying; a sacral lesion alone does not establish safety.[5]

Pharmacologic​

  • Antimuscarinics first-line for DO; combination with β3 agonist when monotherapy inadequate. See Neurogenic Lower Urinary Tract Dysfunction for agent table.
  • Intradetrusor onabotulinumtoxinA 200 U — highly effective for neurogenic DO in SCI; repeat ~6–9 months; patient must be CIC-capable pre-treatment.[4]
  • α-blockers may improve voiding parameters in selected spontaneous voiders; routine use in CIC-dependent patients is not the AUA recommendation.[2]

Surgical​

  • Augmentation cystoplasty — hostile bladder refractory to medical therapy + botulinum. Typically ileum; ileocecal in selected cases.
  • Mitrofanoff / Monti catheterizable channel — wheelchair-dependent patients, obese patients with urethral inaccessibility, patients with prior urethral reconstruction.
  • Bladder-neck closure + continent catheterizable channel — for persistent outlet leakage with CIC-through-channel working.
  • Ileal conduit / continent diversion — salvage when reconstruction has failed or is not feasible.
  • Sacral neuromodulation — AUA/SUFU recommends not offering SNM to patients with SCI or spina bifida; selected use under other neuro-urology guidance or research requires explicit discussion of the limited evidence.[2]
  • External sphincterotomy — largely historical; replaced by CIC + medical therapy in most men.

SCI-specific perioperative caveats​

  • Autonomic dysreflexia — every cystoscopy, urodynamics, and OR case in T6-and-above SCI requires AD prevention: topical lidocaine, BP monitoring, short-acting antihypertensives (nifedipine, nitrate) available. See Autonomic Dysreflexia.
  • Positioning and pressure injury — lithotomy / prone positioning with insensate skin; meticulous padding, frequent repositioning, and postop skin checks.
  • Spasticity — baclofen pumps and botulinum-for-limb-spasticity regimens may interact with bladder care timing.
  • Heterotopic ossification — at hips; affects access and positioning.

Specific Scenarios​

Indwelling catheter exit — transitioning to CIC​

Assess whether CIC is feasible with the patient's dexterity, transfers, caregiver support, and goals. If a chronic indwelling catheter is required, AUA/SUFU favors suprapubic over urethral drainage to limit urethral injury. Neither approach removes infection or stone risk.[2]

Bladder cancer surveillance​

  • Long-term indwelling catheter (>5–10 years) is associated with increased bladder SCC risk.
  • AUA/SUFU recommends against routine screening/surveillance cystoscopy, including in chronic indwelling-catheter users.[1]
  • Any gross hematuria, persistent irritative symptoms, or pelvic pain warrants cystoscopy and clinical evaluation rather than waiting for a scheduled visit.

Fertility and sexual health​

  • Erectile dysfunction — PDE5i first-line; intracavernosal injection or penile prosthesis in refractory cases.
  • Ejaculatory dysfunction — penile vibratory stimulation (PVS) first-line; electroejaculation (EEJ) if PVS fails; retrieved sperm used with IUI / IVF / ICSI.
  • Female SCI — fertility preserved; pregnancy-specific bladder management plan required; delivery planning with OB/GYN.

Aging SCI population​

  • BPH — increasingly common; treating in CIC patients requires balancing outlet resistance (needed for dry intervals between CIC) vs ease of catheter passage.
  • Prostate cancer — screening with PSA in SCI follows general guidelines; transrectal biopsy requires AD prophylaxis.
  • Falls, cognitive decline, caregiver changes — trigger reassessment of feasible bladder management.

Clinical Correlations for the Reconstructive Urologist​

  • Begin safe drainage and arrange reassessment early. Time video-urodynamics to clinical stability and risk; do not use a fixed post-injury waiting period to defer investigation of deterioration.[1]
  • Hostile bladder in SCI is reversible if caught early. Escalate treatment according to measured pressure and compliance; β3-related symptom improvement alone does not prove safe storage. Do not wait for eGFR decline.
  • Care is multidisciplinary. SCI medicine physiatrist, urologist, neuro-urology nurse / educator, physical therapy, and social work are the standard team.
  • Transition from pediatric SCI / spina bifida — aging-out patients need deliberate handoff to adult reconstructive urology; otherwise they fall out of surveillance and present years later with advanced disease.

See Also​

Videos​

Management of Neurogenic Bladder After Spinal Cord Injury
Neurogenic Bladder Research Group (2021)

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

2. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

3. Milligan J, Goetz LL, Kennelly MJ. "A Primary Care Provider's Guide to Management of NLUTD and UTI After Spinal Cord Injury." Top Spinal Cord Inj Rehabil. 2020;26(2):108–115. doi:10.46292/sci2602-108

4. Romo PGB, Smith CP, Cox A, et al. "Non-Surgical Urologic Management of Neurogenic Bladder After Spinal Cord Injury." World J Urol. 2018;36(10):1555–1568. doi:10.1007/s00345-018-2419-z

5. European Association of Urology. Neuro-urology guideline, assisted bladder emptying. 2026. Accessed September 11, 2026.